Advertisement

Drug Metabolism Assays and Their Use in Drug Discovery

  • M. K. Bayliss
  • P. J. Eddershaw
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 37)

Abstract

Arguably the biggest challenge currently facing the global pharmaceutical industry is the urgent need for improvements in productivity in the discovery and development of new medicines. Improved productivity requires enhancements in both efficiency and effectiveness. Thus, in the context of drug discovery it involves a shortening of the time taken from lead identification to full development, but more importantly, a marked increase in the quality of drug candidates provided for development. The consequences of the past practice of taking sub-optimal compounds into development are all too apparent in the high attrition rate of drug candidates during this phase and the oft-repeated fact that the majority of the cost of bringing a new medicine to market is due to those failures (Abelson 1993).

Keywords

Drug Discovery Drug Candidate Metabolic Stability Lead Optimisation Poor Bioavailability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abelson PH (1993) Improvements in health care. Science 260: 11PubMedCrossRefGoogle Scholar
  2. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188–190PubMedCrossRefGoogle Scholar
  3. Eddershaw PJ, Dickins M (1999) Advances in in vitro drug metabolism screening. Pharm Sci Tech Today 2: 13–19CrossRefGoogle Scholar
  4. Frick LW, Adkison KK, Wells-Knecht KJ, Woollard P, Higton DM (1998) Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharm Sci Tech Today 1 12–18CrossRefGoogle Scholar
  5. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88: 28–33PubMedCrossRefGoogle Scholar
  6. Korfmacher WA, Cox KA, Bryant MS, Veals Ng K, Watkins R, Lin CC (1997) HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. Drug Discov Today 2: 532–537CrossRefGoogle Scholar
  7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Ad Drug Del Rev 23: 3–25CrossRefGoogle Scholar
  8. Watt AP, Morrison D, Evans DC (2000) Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discov Today 5: 17–24PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • M. K. Bayliss
  • P. J. Eddershaw

There are no affiliations available

Personalised recommendations